Royal Adelaide Hospital

Ferronova raises another $6 million to advance image-guided cancer surgery

Adelaide medtech Ferronova has banked another $6 million from returning backers to advance its surgical tracer for cancer, lifting Series A funding to $17.5 million; backer parent UltraGreen.ai floated in Singapore this month.

Also movefm.com.au

Biotech Ferronova boosts Series A capital raise by $6m

Adelaide biotech Ferronova added $6 million to its Series A from prior backers, lifting the round's total to $17.5 million; backer Renew's parent Ultragreen.ai floated in Singapore this month.

Also ferronova.com.au·movefm.com.au·Biotech Dispatch·Startup Daily

Micro-X miniature CT scanner to enter clinical trials

Micro-X will trial its lightweight portable CT brain scanner at two hospitals this year; the Adelaide company's stroke technology was developed with $8 million in grant funding, as was rival EMVision's approach.

EBR Systems meets endpoints early in pivotal SOLVE-CRT trial: paves way for FDA approval application and commercialisation

Cardiac pacing company EBR Systems says its SOLVE-CRT trial hit its safety and efficacy goals early, keeping a 2024 US approval bid on course; the article also recalls its 2021 ASX listing.

Also Brandon BioCatalyst portfolio

‘No tumour will go undetected’: Ferronova lands $11 million for its cancer hunting nanotechnology

Adelaide biotech Ferronova raised $11 million for its cancer-detection nanotechnology, with Renew Pharmaceuticals and a government CRC contributing, following an earlier $4.6 million Series A in 2020.

Also SmartCompany

South Australian biotech startup Ferronova banks $11 million to tackle cancer treatment

Adelaide cancer-focused biotech Ferronova has secured fresh backing: an investor round led by Irish strategic partner Renew Pharmaceuticals plus a federal research grant, to speed clinical trials in stomach and brain cancers.

Also SmartCompany·SmartCompany·SmartCompany·Startup Daily·Business News Australia·Startup Daily

Ferronova secures A$11 million to advance nanotech image-guided cancer therapy

Adelaide biotech Ferronova announced an A$11 million package: an A$8 million round led by Ireland's Renew Pharmaceuticals plus an A$3 million government CRC-P grant, with existing shareholders Uniseed and Artesian also participating.

Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment

Glyscend reports encouraging Phase 1 biomarker data for its diabetes drug GLY-200, announces US FDA clearance of its investigational new drug application, and has begun enrolling patients in a Phase 2 trial.

Glyscend Therapeutics commences South Australia Phase I clinical trial to progress new type 2 diabetes treatment

Glyscend Therapeutics, a Johns Hopkins spin-out, is starting a Phase I trial of its type 2 diabetes pill in Adelaide; the piece recalls its AUD$29 million Series A led by Brandon Capital's MRCF.

Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio

Adelaide Type 2 Diabetes researchers zero in on an ‘operation in a pill’

Adelaide-backed biotech Glyscend is recruiting volunteers for phase 1 trials of a pill mimicking gastric bypass surgery to treat type 2 diabetes, funded with $29 million from Brandon Capital's MRCF, Santé Ventures and Breakout Labs.

Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio

Adelaide Type 2 Diabetes researchers zero in on an 'operation in a pill'

Glyscend Therapeutics, an Adelaide-Baltimore biotech, is recruiting volunteers for phase 1 trials of GLY-200, a pill mimicking gastric bypass for type 2 diabetes, developed with $29 million from MRCF, Santé Ventures and Breakout Labs.

Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio

Innovative type two diabetes treatment scores $29m

Glyscend's diabetes pill has raised $29 million with backing from Brandon Capital, Santé Ventures and Breakout Labs, ahead of planned human trials in Adelaide.

Also Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio

Australian Phase II trial commences for potential world-first treatment of viral conjunctivitis

Okogen has begun Australian Phase II trials of its conjunctivitis therapy OKG-0301 across multiple sites, with Brandon Capital's MRCF having invested in the biotech's Series A in December 2017.

Also Brandon BioCatalyst portfolio